Literature DB >> 2072118

Serum creatine-kinase (CK) and pyruvate-kinase (PK) activities in Duchenne (DMD) as compared with Becker (BMD) muscular dystrophy.

M Zatz1, D Rapaport, M Vainzof, M R Passos-Bueno, E R Bortolini, R de C Pavanello, C A Peres.   

Abstract

Serum creatine-kinase (CK) activities were determined in 536 patients affected with X-linked muscular dystrophy (456 with Duchenne or DMD and 80 with Becker or BMD) and serum pyruvate-kinase (PK) in 360 among them (309 DMD and 51 BMD). The aim of this investigation was to assess the variability and rate of decrease in serum activity in DMD as compared with BMD as a function of age and in DMD as a function of Vignos scale as well. In DMD, maximum CK and PK activities were found around 1-6 years old and the average rate of decline according to age was estimated as 0.18 per year and 0.27-0.29 for both enzymes as a function of Vignos scale (assessed in 291 cases). For BMD, maximum serum enzyme levels were found around 10-15 years old and the rate of decline of serum activity per year was 0.06 for CK and 0.07 for PK. If maximum levels of serum enzyme reflect active muscle degeneration and the rate of decline per year to progressive loss of muscle mass (responsible for the release of muscle enzymes to the blood stream) our observations suggest: (a) active muscle degeneration occurs, on average, 5 years later in the group of outliers and 10 years later in BMD as compared with severe DMD; (b) the rate in which muscle mass is lost is significantly greater in DMD than in BMD and therefore serum enzyme determinations may represent an important test for evaluation of therapeutic trials; (c) serum enzymes determination may represent an important preliminary test to discriminate in a proportion of young patients if they will develop a severe or milder phenotype.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2072118     DOI: 10.1016/0022-510x(91)90068-i

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  48 in total

1.  Three novel serum biomarkers, miR-1, miR-133a, and miR-206 for Limb-girdle muscular dystrophy, Facioscapulohumeral muscular dystrophy, and Becker muscular dystrophy.

Authors:  Yasunari Matsuzaka; Soichiro Kishi; Yoshitsugu Aoki; Hirofumi Komaki; Yasushi Oya; Shin-Ichi Takeda; Kazuo Hashido
Journal:  Environ Health Prev Med       Date:  2014-08-24       Impact factor: 3.674

2.  A model to estimate the expression of the dystrophin gene in muscle from female Becker muscular dystrophy carriers.

Authors:  M Vainzof; M R Passos-Bueno; R C Pavanello; R Schreiber; M Zatz
Journal:  J Med Genet       Date:  1992-07       Impact factor: 6.318

3.  Clinical Utility Gene Card for: Becker muscular dystrophy.

Authors:  David Coote; Mark R Davis; Macarena Cabrera; Merrilee Needham; Nigel G Laing; Kristen J Nowak
Journal:  Eur J Hum Genet       Date:  2018-02-21       Impact factor: 4.246

4.  Clinical Follow-Up for Duchenne Muscular Dystrophy Newborn Screening: A Proposal.

Authors:  Jennifer M Kwon; Hoda Z Abdel-Hamid; Samiah A Al-Zaidy; Jerry R Mendell; Annie Kennedy; Kathi Kinnett; Valerie A Cwik; Natalie Street; Julie Bolen; John W Day; Anne M Connolly
Journal:  Muscle Nerve       Date:  2016-06-13       Impact factor: 3.217

5.  Action of obestatin in skeletal muscle repair: stem cell expansion, muscle growth, and microenvironment remodeling.

Authors:  Uxía Gurriarán-Rodríguez; Icía Santos-Zas; Jessica González-Sánchez; Daniel Beiroa; Viviana Moresi; Carlos S Mosteiro; Wei Lin; Juan E Viñuela; José Señarís; Tomás García-Caballero; Felipe F Casanueva; Rubén Nogueiras; Rosalía Gallego; Jean-Marc Renaud; Sergio Adamo; Yolanda Pazos; Jesús P Camiña
Journal:  Mol Ther       Date:  2015-03-12       Impact factor: 11.454

6.  Cosegregation of schizophrenia with Becker muscular dystrophy: susceptibility locus for schizophrenia at Xp21 or an effect of the dystrophin gene in the brain?

Authors:  M Zatz; H Vallada; M S Melo; M R Passos-Bueno; A H Vieira; M Vainzof; M Gill; V Gentil
Journal:  J Med Genet       Date:  1993-02       Impact factor: 6.318

7.  The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history.

Authors:  K M Bushby; D Gardner-Medwin
Journal:  J Neurol       Date:  1993-02       Impact factor: 4.849

Review 8.  Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Miranda D Grounds; Hannah G Radley; Gordon S Lynch; Kanneboyina Nagaraju; Annamaria De Luca
Journal:  Neurobiol Dis       Date:  2008-04-09       Impact factor: 5.996

9.  Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis.

Authors:  L V Nicholson; M A Johnson; K M Bushby; D Gardner-Medwin; A Curtis; I B Ginjaar; J T den Dunnen; J L Welch; T J Butler; E Bakker
Journal:  J Med Genet       Date:  1993-09       Impact factor: 6.318

Review 10.  Current understanding and management of dilated cardiomyopathy in Duchenne and Becker muscular dystrophy.

Authors:  Rita Wen Kaspar; Hugh D Allen; Federica Montanaro
Journal:  J Am Acad Nurse Pract       Date:  2009-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.